Drugs / L-BLP25
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT01731587 | Jan 2001 → ? | non-small cell lung carcinoma | Merck KGaA, Darmstadt, Germany | Withdrawn | No outcome recorded |
| Phase 21 trial · 1 missed | ||||||
| Phase 2 | NCT01462513 | Aug 2011 → Dec 2017 | colon carcinoma, rectal carcinoma | Prof. Dr. Carl Schimanski | Completed | Missed primary |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | L-BLP25 | “Eight consecutive weekly subcutaneous administration with reconstituted L-BLP25 (containing 806 microgram of BLP25 lipopeptide) followed by administrations at 6-week intervals,...” NCT01731587 ↗ |
| Modality | Vaccine | “L-BLP25 is a cancer vaccine that targets MUC1” NCT01462513 ↗ |
| Route | Subcutaneous | “Eight consecutive weekly subcutaneous administration with reconstituted L-BLP25” NCT01731587 ↗ |
| Target | MUC1 | “L-BLP25 is a cancer vaccine that targets MUC1” NCT01462513 ↗ |